Joachim Robert Kalden

from Wikipedia, the free encyclopedia

Joachim Robert Kalden (born November 23, 1937 in Marburg ) is a German immunologist and rheumatologist with a focus on pathogenesis research in autoimmune diseases and a professor at the Friedrich-Alexander-Universität Erlangen-Nürnberg .

Life

After Joachim Robert Kalden received his Abitur in 1958 in Frankenberg (Eder) , he studied medicine at the universities in Freiburg , Marburg and Tübingen . He completed his dissertation on the subject of immunological histamine release in the diagnosis of drug-allergic conditions in 1966 at the University Clinic for Internal Medicine under the direction of Hans Erhard Bock . He then worked from 1967 to 1970, first as a fellow and later as a research assistant, at the Department of Therapeutics and the Medical Research Council of the University of Edinburgh , interrupted by several stays at the National Institutes of Health in Bethesda , Maryland .

Back in Germany, Kalden was an assistant at the Department of Internal Medicine at the Hannover Medical School , where he completed his habilitation there in 1973 on animal experiments on the pathogenesis of myasthenia gravis . In Hanover he also acquired his specialist in internal medicine and was senior physician in the department for clinical immunology, rheumatology and transfusion medicine from 1974 to 1976. In 1977 he followed a call to the chair for clinical immunology and rheumatology at the Friedrich-Alexander-Universität Erlangen-Nürnberg and in the same year became director of the then Institute and Polyclinic for Clinical Immunology at Krankenhausstrasse 12, today's Medical Clinic 3 for Rheumatology and Immunology , appointed. Starting in small relationships with two senior physicians, four assistants and two medical-technical assistants , he was able to develop the institute into a leading research center, at which two clinical Max Planck working groups were established in 1988 . He retired on March 31, 2006 .

In 1976 Kalden received the Georg Zimmermann Prize for Tumor Research from the Hannover Medical School and in 2005 the international prize from the Japan College for Rheumatology. The Charité in Berlin awarded him an honorary doctorate in 1998 and in 2005 he received an honorary doctorate from the Medical Faculty of Lund University . He has been a full member of the Bavarian Academy of Sciences, Section IV (natural sciences, life sciences, medicine) since 1999 and was elected a member of the German Academy of Sciences Leopoldina for the Internal Medicine and Dermatology Section on September 11, 2002 . Kalden has been the recipient of the Federal Republic of Germany's Cross of Merit on Ribbon since 1996 and of the Bavarian Order of Merit since 2000 .

From 1983 to 1990 Kalden was President of the German Society for Immunology , 1993/1994 President of the German Society for Rheumatology and from 2001 to 2003 President of the European League against Rheumatism (EULAR). For more than a decade, he headed the international science committee of the German Cancer Research Center . In addition, he organized and co-organized numerous scientific congresses, such as the 7th International Congress of Immunology in Berlin in 1989.

Works (selection)

author

  • JR Kalden et al .: Immunosuppressive effects of apoptotic cells . In: Nature . Volume 390, 1997, pp. 350–351 , doi : 10.1038 / 37022 (English).
  • JR Kalden et al .: Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus . In: Arthritis & Rheumatology . Volume 41, Issue 7, 1998, pp. 1241-1250 , doi : 10.1002 / 1529-0131 (199807) 41: 7 <1241 :: AID-ART15> 3.0.CO; 2-H (English).
  • JR Kalden et al .: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis . In: Arthritis & Rheumatology . Volume 41, Issue 9, 1998, pp. 1552-1563 , doi : 10.1002 / 1529-0131 (199809) 41: 9 <1552 :: AID-ART5> 3.0.CO; 2-W (English).
  • JR Kalden et al .: Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial . In: The Lancet . Volume 354, Issue 9194, 1999, pp. 1932–1939 , doi : 10.1016 / S0140-6736 (99) 05246-0 (English).
  • JR Kalden et al .: Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis . In: The New England Journal of Medicine . Volume 343, 2000, pp. 1594-1602 , doi : 10.1056 / NEJM200011303432202 (English).
  • JR Kalden et al .: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial . In: The Lancet . Volume 363, Issue 9410, 2004, pp. 675-681 , doi : 10.1016 / S0140-6736 (04) 15640-7 (English).

editor

swell

Web links